In summary, our study demonstrates that A20 is remarkably up-regulated in melanoma and plays an oncogenic role by simultaneously promoting tumor growth and metastasis, and rendering the acquired resistance to BRAF-targeted therapy. Here, BRAF is linked to melanoma.